


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in this application:

1. (Currently Amended) A method of inhibiting cancer development in pre-cancerous cells comprising the administration to a subject in need thereof of an effective amount of a fatty acid synthase inhibitor.
2. (Original) A method according to claim 1 wherein the subject is a mammal.
3. (Original) A method according to claim 1 wherein the subject is a human.
4. (Original) A method according to claim 1 wherein the subject has pre-cancerous lesions.
5. (Currently Amended) A method according to claim ~~4~~ 5 wherein the pre-cancerous lesions express fatty acid synthase.
6. (Original) A method according to claim 5 wherein the pre-cancerous lesions express the *neu* protein.
7. (Original) A method according to claim 5 wherein the pre-cancerous lesions express fatty acid synthase and the *neu* protein.
8. (Original) A method according to claim 5 wherein the pre-cancerous lesions are in a tissue type selected from the group consisting of breast, prostate, colon, lung, stomach, mouth, and bile duct.
9. (Withdrawn) A method according to claim 8 wherein the tissue type is breast.
10. (Withdrawn) A method according to claim 8 wherein the tissue type is prostate.

11. (Withdrawn) A method according to claim 8 wherein the tissue type is colon.
12. (Original) A method according to claim 8 wherein the tissue type is lung.
13. (Withdrawn) A method according to claim 8 wherein the tissue type is stomach.
14. (Withdrawn) A method according to claim 8 wherein the tissue type is mouth.
15. (Withdrawn) A method according to claim 8 wherein the tissue type is bile duct.
16. (Original) A method according to claim 1 wherein the effective amount is in the range from about 60 mg/kg to about 7.5 mg/kg per day.
17. (Original) A method according to claim 1 wherein the fatty acid synthase inhibitor is a compound that directly inhibits the fatty acid synthase enzyme.
18. (Withdrawn) A method according to claim 1 wherein the fatty acid synthase inhibitor is a compound having the following formula:




wherein:

- R¹ = H, C₁-C₂₀ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, -CH₂OR⁵, -C(O)R⁵, -CO(O)R⁵, -C(O)NR⁵R⁶, -CH₂C(O)R⁵, or -CH₂C(O)NHR⁵, where R⁵ and R⁶ are each independently H, C₁-C₁₀ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing one or more halogen atoms.
- R² = -OH, -OR⁷, -OCH₂C(O)R⁷, -OCH₂C(O)NHR⁷, -OC(O)R⁷, -OC(O)OR⁷, -OC(O)NR⁷R⁸, where R⁷ and R⁸ are each independently H, C₁-C₂₀ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, and where R⁷ and R⁸ can each optionally contain

halogen atoms;
 R^3 and R^4 , the same or different from each other, are C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

19. (Currently Amended) A method according to claim 1 wherein the fatty acid synthase inhibitor is a compound having the following formula:



wherein:

R^9 = H, or C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $=CHR^{11}$, $-C(O)OR^{11}$, $-C(O)R^{11}$, $-CH_2C(O)OR^{11}$, $-CH_2C(O)NHR^{11}$, where R^{11} is H or C_1 - C_{10} alkyl, cycloalkyl, or alkenyl;
 R^{10} = C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;
 X = $-OR^{12}$, or $-NHR^{12}$, where R^{12} is H, C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R^{12} group optionally containing a carbonyl group, a carboxyl group, a carboxamide group, an alcohol group, or an ether group, the R^{12} group further optionally containing one or more halogen atoms;
with the proviso that when R^9 is $=CH_2$, then X is not -OH.

20. (Original) A method according to claim 1 wherein the fatty acid synthase inhibitor is tetrahydro-3-methylene-2-oxo-5-n-octyl-4-furancarboxylic acid.